Michael B Hoffman

Director Michael B Hoffman purchases 76,344 shares at $1.87 avg (ANVS); 0 of 5 prior buys at ticker were well-timed at 90-day mark.

Michael B Hoffman, a Director, executed 3 separate purchases totaling 76,344 shares for $142,778.91 at a blended average price of $1.87 on 2026-05-20. His same-ticker history at ANVS shows a consistent pattern of poor execution timing: across 5 prior buys, 0 of 5 were well-timed at the 90-day mark, with prior 90-day returns ranging from -2.9% to -42.6%. The current price of $2.15 is -60.9% from the 52-week high of $5.50, and the company reported revenue of $0.00 in its latest quarter with net income of -$17,606,382.00. This purchase represents an addition of 76,344 shares (+2.3%) to his existing 3,288,539 share position, but the persistent pattern of unfavorable timing outcomes and the company's unprofitable status warrant scrutiny of the underlying investment thesis.

Director Michael B Hoffman purchased 713,800 ANVS shares at $2.10 (Apr 2, 2026); prior buys at ticker show 0 of 5 well-timed (+27.7% stake).

Michael B Hoffman, a Director, acquired 713,800 shares at $2.10 on 2026-04-02, raising his holdings to 3,288,539 shares (+27.7% vs pre-transaction). The current price of $2.28 represents only a +8.6% return from his purchase and sits -55.3% below the 52-week high of $5.10. His prior trades at Annovis Bio show a concerning pattern: 5 previous buys across late 2025 resulted in negative 30-day and 90-day returns on every occasion, with 0 of 5 proving well-timed at the 90-day mark. The company's fundamentals offer limited reassurance—revenue stands at $0.00 for the latest quarter and net income is $-7,262,658.00, indicating ongoing losses without revenue generation. This latest purchase follows a 30-day decline of -11.6% and a 90-day decline of -37.5%, extending a pattern of unfavorable entry timing at this specific ticker.

Director Hoffman purchases 45,000 ANVS shares for $193,794.00 across 2 transactions on 2025-12-08

Director Michael B Hoffman executed 2 separate open-market purchases totaling 45,000 shares ($193,794.00) on 2025-12-08, adding 1.8% to his existing holdings of 2,529,739 shares. The purchases occur within days of his prior 5 buys at ANVS on 2025-11-24 and 2025-11-21, establishing a pattern of consistent accumulation at this ticker over a two-week window. However, despite a 90-day return of +82.2% and a 30-day return of +115.0%, his prior 5 same-ticker purchases remain too recent to measure outcome (outcomes not yet measurable), preventing any assessment of whether these recent acquisitions align with genuine conviction or are part of a mechanical pattern. The company's fundamentals present substantial headwinds: zero revenue in the latest quarter and net losses of $7,262,658.00, with consistent unprofitability over the full fiscal year. At the blended price of $4.31 against current price of $4.30, this filing offers limited signal regarding insider confidence in near-term direction.

Director Hoffman buys 39,200 shares at $4.08 average, adding $159,886.07 to 2.52M-share position at ANVS.

Michael B. Hoffman, a Director at Annovis Bio, executed 4 separate purchases totaling 39,200 shares for $159,886.07 on November 24, 2025, at prices ranging from $3.85 to $4.15 per share with a blended average of $4.08. This transaction increases his holdings to 2,519,739 shares, a +1.6% increase from prior holdings of 2,480,539 shares. The timing follows aggressive recent price appreciation: the stock has gained +135.1% over the prior 30 days and +105.1% over 90 days, yet trades at -33.8% from its 52-week high of $7.28. Annovis Bio remains materially unprofitable with net income of $-7,262,658.00 and zero revenue in the latest quarter, generating substantial execution risk. Prior trades by Hoffman at this ticker (4 buys on 2025-11-21, 2025-11-21, 2025-11-14, and 2025-10-28) have not yet reached measurable 90-day outcome windows, leaving no established track record to assess timing accuracy at this specific security.

Director Michael B Hoffman bought 20,000 shares at $3.49–$3.50 on 2025-11-21 for $69,900.00 at ANVS

Michael B Hoffman, a director at Annovis Bio, executed 2 purchases totaling 20,000 shares for $69,900.00 on 2025-11-21 at prices of $3.49 and $3.50, bringing his holdings to 2,490,539 shares. The purchases follow two prior buys at this ticker within the past month (2025-11-14 and 2025-10-28), suggesting consecutive accumulation activity during a period of price volatility. ANVS trades at $3.79 currently, 47.9% below its 52-week high of $7.28, though the stock has risen 86.7% over the past 30 days from depressed levels. The company is unprofitable (net income $-7,262,658.00 in the latest quarter) with zero revenue reported, creating a speculative risk profile where insider accumulation must be weighed against fundamental weakness and the timing of recent momentum.

Director Hoffman purchases 15,000 ANVS shares at $2.11; holds 2,470,539 shares post-transaction amid -54.5% drawdown from 52-week high.

Hoffman Michael B, as Director of Annovis Bio, purchased 15,000 shares at $2.11 on 2025-11-14, expanding his holdings to 2,470,539 shares. This marks his second purchase at ANVS in as many weeks (prior buy on 2025-10-28), indicating continued accumulation despite the stock trading at -54.5% from its 52-week high of $7.41. However, context reveals material headwinds: the company reported zero quarterly revenue and a net loss of $-7,262,658.00, with a market capitalization of only $89,314,735.93. The stock has recovered +70.2% over the past 30 days and +35.3% over 90 days, suggesting recent momentum recovery from depressed levels. Investors should note that while the director's recent sequential purchases could reflect conviction in recovery, the company's unprofitability and lack of revenue limit the evidentiary weight of insider buying in isolation.

Director Hoffman buys 975,610 shares of ANVS for $2.0M at $2.05, increasing stake 65.9% to 2.46M shares

Hoffman Michael B (Director) purchased 975,610 shares at $2.05 on 2025-10-28 for $2,000,000.50, a substantial $2.0M commitment that increased his holdings by 65.9% to 2,455,539 shares. This represents one of the largest director acquisitions in the company's history by value. The purchase occurs amid significant headwinds: Annovis Bio generated $0.00 revenue in its latest quarter, reported net income of $-7,262,658.00, and trades at $2.43 — a 71.8% decline from its 52-week high of $8.61. The stock has recovered 46.4% over the past 30 days but remains deeply underwater year-to-date, suggesting the director acquired shares during a period of severe drawdown when the market had priced the company near crisis lows.